Key result
Anti-cTnI auto-antibodies linked to a lack of LVEF improvement 6-9 months post-AMI.
Why the study?
Auto-antibodies to cTnI occur in acute coronary syndrome, but their clinical relevance remains largely unknown.
Does the presence of auto-antibodies against cardiac troponin I predict a lack of improvement in left ventricular function after acute myocardial infarction?
Population
272 patients with DCM, 185 with ICM, and 108 with AMI
Comparison
cTnI-Ab positive vs cTnI-Ab negative
Design
Observational cohort study
Follow-up
6-9 months
Authors
Loading...
Absence of cTnI-Ab may identify patients with greater LV recovery post-MI; leaves open whether autoimmunity modulates remodeling.
Cohort (n=565)
Does the presence of auto-antibodies against cardiac troponin I predict a lack of improvement in left ventricular function after acute myocardial infarction?
The presence of auto-antibodies against cardiac troponin I in patients with acute myocardial infarction is associated with a lack of improvement in left ventricular ejection fraction over 6-9 months.
Leuschner et al. (2008) conducted a cohort in Dilated cardiomyopathy, ischaemic cardiomyopathy, and acute myocardial infarction (n=565). Presence of anti-cTnI auto-antibodies (titre ≥1:160) vs. Absence of anti-cTnI auto-antibodies was evaluated on Improvement in left ventricular ejection fraction (LVEF) and stroke volume. Among 108 patients with acute myocardial infarction, the 10 patients positive for anti-cTnI auto-antibodies showed no significant increase in LVEF at 6-9 months, unlike antibody-negative patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: